Virtual Radiologic Corp Announces First Quarter 2010 Financial Results

Reports First Quarter Revenue up 8 Percent to $30.8 Million; Adjusted EBITDA up 25 Percent to $7.0 Million

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Virtual Radiologic Corporation (NASDAQ:VRAD), a national radiology practice and a leader in the development of radiologist workflow technology, today reported financial results for the first quarter ended March 31, 2010.

First Quarter Financial Highlights

  • Read volume up 14% to 700,000
  • Finals volume grew 37%, representing 32% of total volume
  • Revenue up 8% to $30.8 million
  • Adjusted EBITDA(1) up 25% to $7.0 million and 23% of revenue
  • Adjusted net income(2) up 25% to $3.1 million; adjusted diluted earnings per share(3) (EPS) up 27% to $0.19
  • GAAP net income up 40% to $2.0 million; GAAP diluted EPS up 33% to $0.12
  • Cash of $52.4 million; the Company has no debt

Additional First Quarter Highlights

  • U.S. Patent Office approves patent covering several applications within vRad’s technology portfolio
  • Stevie award winner for technology-enabled customer service

“We are pleased with our first quarter financial performance,” said Rob Kill, Virtual Radiologic’s president and chief executive officer. “The recent patent approval and the Stevie award are strong validations of our technology focus that differentiates us in the radiology market.”

First Quarter Results

Total revenue increased 8% to $30.8 million for the quarter ended March 31, 2010, compared to $28.6 million for the quarter ended March 31, 2009. The increase in revenue over the first quarter of 2009 resulted primarily from a 15% increase in the number of hospitals and medical facilities served to 1,205 as of March 31, 2010, representing approximately 21% of all hospitals in the United States.

Adjusted EBITDA increased 25% to $7.0 million for the quarter ended March 31, 2010, compared to $5.6 million for the quarter ended March 31, 2009. Adjusted EBITDA was 23% of revenue for the quarter ended March 31, 2010, compared to 20% for the prior year period.

Adjusted net income increased 25% to $3.1 million for the quarter ended March 31, 2010, compared to $2.5 million for the quarter ended March 31, 2009. This resulted in adjusted diluted EPS of $0.19 for the quarter ended March 31, 2010, compared to $0.15 for the quarter ended March 31, 2009.

GAAP net income was $2.0 million for the quarter ended March 31, 2010, compared to $1.4 million for the quarter ended March 31, 2009, resulting in diluted earnings per share of $0.12 for the quarter ended March 31, 2010, compared to $0.09 for the quarter ended March 31, 2009.

Conference Call Information

The Company will conduct a conference call and live webcast to discuss these results at 4:30 p.m. Eastern Time on April 26, 2010. The conference call will include prepared remarks by senior management, followed by a question and answer session. To access the conference call, dial (866) 362-5158 (United States and Canada), or (617) 597-5397 (outside the United States and Canada), and use passcode 15168404. The live webcast will also be available in the Investor Relations section of vRad’s website at http://ir.virtualrad.com under "Calendar of Events." The webcast will be archived shortly after the call for on-demand replay. In addition, a telephone replay of the conference call will be available from 7:30 p.m. Eastern Time on Monday, April 26, through midnight on Monday, May 3, 2010. To access the telephone replay, dial (888) 286-8010 (United States and Canada), or (617) 801-6888 (outside the United States and Canada), and use passcode 71123873.

About Virtual Radiologic

Virtual Radiologic Corporation (vRad) is a national radiology practice working in partnership with local radiologists and hospitals to optimize radiology's pivotal role in patient care. vRad's more than 140 affiliated radiologists serve 1,170-plus facilities (nearly 21% of U.S. hospitals), reading 2.7 million studies annually. Delivering unparalleled access to subspecialty expertise, vRad contributes to improved quality of patient care. And with our next-generation technology, vRad enhances productivity, helping to lower the overall cost of care while expediting time of diagnosis and treatment. For more information, visit www.vrad.com.

Safe Harbor for Forward-Looking and Cautionary Statements

Certain statements in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, in particular, statements about plans, objectives, strategies and prospects regarding, among other things, vRad’s business and results of operations. These statements can be identified by the use of words such as “will,” “believe,” “expect,” and “anticipate” and similar terms or expressions of future expectation. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance or achievements of vRad to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. For examples of such risks and uncertainties, please see vRad’s Annual Report on Form 10-K, as well as other filings with the Securities and Exchange Commission. vRad undertakes no duty to update these forward-looking statements due to new information or as a result of future events.

Notes Regarding the Use of Non-GAAP Financial Measures

vRad records its results of operations in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In addition, vRad is providing certain supplemental non-GAAP information which the Company believes to be an important indicator of its financial performance. vRad uses the following non-GAAP financial measures:

  • Adjusted EBITDA – net income excluding the net effects of interest, income taxes, depreciation and amortization, non-cash stock-based compensation expense and medical malpractice loss reserves;
  • Adjusted net income – net income excluding the effects of non-cash stock-based compensation, net of tax, and medical malpractice loss reserves, net of tax; and
  • Adjusted diluted earnings per share – adjusted net income divided by weighted average diluted shares outstanding.

vRad presents these non-GAAP financial measures because it believes that they are a useful indicator of its performance and on-going operations. The Company believes that these non-GAAP financial measures are useful to investors in part because such measures are frequently used by securities analysts to measure a company’s operating performance without regard to certain items, such as income tax expense, net interest income and depreciation and amortization, which can vary substantially from company to company. vRad’s management also uses these non-GAAP financial measures in order to review and assess its operating performance and its management team in connection with certain incentive programs and the preparation of its financial projections.

Adjusted EBITDA, adjusted net income and adjusted diluted earnings per share are not measurements of the Company’s financial performance under GAAP and may not be comparable to the calculation of similarly titled measures reported by other companies. These measures should not be considered as an alternative to net income, earnings per share or any other performance measures derived in accordance with GAAP.

(1) Adjusted EBITDA consists of net income excluding the net effects of interest, income taxes, depreciation and amortization, non-cash stock-based compensation expense and medical malpractice loss reserves (other than specific case reserves). See “Notes Regarding the Use of Non-GAAP Financial Measures” and “Supplemental Information and Non-GAAP Reconciliations” for more information related to adjusted EBITDA.

(2) Adjusted net income consists of net income excluding the effects of non-cash stock-based compensation, net of tax, and medical malpractice loss reserves (other than specific case reserves), net of tax. See “Notes Regarding the Use of Non-GAAP Financial Measures” and “Supplemental Information and Non-GAAP Reconciliations” for more information related to adjusted net income.

(3) Adjusted diluted earnings per share consists of adjusted net income divided by weighted average diluted shares outstanding. See “Notes Regarding the Use of Non-GAAP Financial Measures” and “Supplemental Information and Non-GAAP Reconciliations” for more information related to adjusted diluted earnings per share.

 
VIRTUAL RADIOLOGIC CORPORATION
   
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(in thousands, except per share data)
 
 
Three Months Ended March 31,
2010 2009
 
Revenue $ 30,813   $ 28,568  
 
Operating costs and expenses
Professional services 15,124 13,766
Sales, general and administrative 10,641 11,066
Depreciation and amortization   1,872     1,450  
Total operating costs and expenses   27,637     26,282  
 
Operating income 3,176 2,286
 
Other income (expense)
Interest income 45 57
Interest expense   (1 )   (1 )
Total other income   44     56  
 
Income before income tax expense 3,220 2,342
 
Income tax expense   1,266     950  
Net income $ 1,954   $ 1,392  
 
 
Earnings per common share
Basic $ 0.12 $ 0.09
Diluted $ 0.12 $ 0.09
Weighted average common shares outstanding
Basic 15,949 15,863
Diluted 16,305 16,240
 
 
         
SUPPLEMENTAL NON-GAAP FINANCIAL MEASURES
(Unaudited)
(in thousands, except per share data)
 
Three Months Ended March 31,
2010 2009
Adjusted EBITDA(1) $ 6,997 $ 5,614
Adjusted net income(1) $ 3,137 $ 2,509
Adjusted diluted earnings per share(1) $ 0.19 $ 0.15
 
(1) See “Notes Regarding the Use of Non-GAAP Financial Measures” and “Supplemental Information and Non-GAAP Reconciliations” for more information related to the non-GAAP financial measures presented in this table.
 
 
VIRTUAL RADIOLOGIC CORPORATION
   
SUPPLEMENTAL INFORMATION AND NON-GAAP RECONCILIATIONS
(Unaudited)
(in thousands, except per share data)
 
         
The following table reconciles the GAAP financial measure of Net income to the non-GAAP supplemental financial measure of Adjusted EBITDA which excludes the effects of interest, income taxes, depreciation and amortization, non-cash stock-based compensation expense, and medical malpractice loss reserves. See "Notes Regarding the Use of Non-GAAP Financial Measures" for more information related to the non-GAAP financial measures presented in this table.
Three Months Ended
March 31,
2010 2009
 
Reconciliation of Net income to Adjusted EBITDA:
 
Net income $ 1,954   $ 1,392  
Income tax expense 1,266 950
Other income, net (44 ) (56 )
Depreciation and amortization   1,872     1,450  
EBITDA   5,048     3,736  
Physician non-cash stock-based compensation 11 (143 )
Employee non-cash stock-based compensation 577 721
Medical malpractice loss reserves   1,361     1,300  
Adjusted EBITDA $ 6,997   $ 5,614  
         
         
The following table reconciles the GAAP financial measures of Net income and Diluted earnings per share to the non-GAAP supplemental financial measures of Adjusted net income and Adjusted diluted earnings per share which exclude the effects of non-cash stock-based compensation expense, net of tax, and medical malpractice loss reserves, net of tax. See "Notes Regarding the Use of Non-GAAP Financial Measures" for more information related to the non-GAAP financial measures presented in this table.
Three Months Ended
March 31,
2010 2009
 
Reconciliation of Net income to Adjusted net income:
 
Net income $ 1,954   $ 1,392  
Physician non-cash stock-based compensation, net of tax 7 (85 )
Employee non-cash stock-based compensation, net of tax 350 429
Medical malpractice loss reserves, net of tax   826     773  
Adjusted net income $ 3,137   $ 2,509  
 
Reconciliation of Diluted earnings per share to Adjusted diluted earnings per share:
 
Diluted earnings per share $ 0.12   $ 0.09  
Physician non-cash stock-based compensation, net of tax 0.00 (0.01 )
Employee non-cash stock-based compensation, net of tax 0.02 0.03
Medical malpractice loss reserves, net of tax   0.05     0.04  
Adjusted diluted earnings per share $ 0.19   $ 0.15  
 

Weighted average diluted shares outstanding

16,305

16,240

                 
 
VIRTUAL RADIOLOGIC CORPORATION
       
CONDENSED CONSOLIDATED BALANCE SHEETS AND SELECTED OPERATING DATA
(Unaudited)
 
 
As of As of
March 31, December 31,
2010 2009
(in thousands)
 
Cash and cash equivalents $ 52,392 $ 50,163
Accounts receivable, net 18,451 17,384
Other current assets 4,384 4,519
Other assets   21,714     22,396  
Total assets $ 96,941   $ 94,462  
 
Current liabilities $ 13,901 $ 15,074
Other liabilities   11,261     10,054  
Total liabilities 25,162 25,128
Total stockholders' equity   71,779     69,334  
Total liabilities and stockholders' equity $ 96,941   $ 94,462  
 
 
As of March 31,
2010 2009
Affiliated radiologists providing services 144 134
Customers 658 625
Hospitals and other medical facilities served 1,205 1,050
 
 
Three Months Ended
March 31,
2010 2009
 
Total reads 700,443 613,117
Percentage growth over prior year period 14 % 30 %
Same site volume growth(1) 5 % 2 %
Percentage of read volume from final reads 32 % 27 %
 
(1) Same-site volume growth is calculated as the percentage increase in the number of reads over the comparable prior year period generated by a facility that has been under contract for at least three months at the beginning of the measurement period and remains a customer throughout that period.
 



CONTACT:

Virtual Radiologic Corporation
Len Purkis, 952-595-1196
Chief Financial Officer
[email protected]
http://www.vrad.com

KEYWORDS:   United States  North America  Minnesota

INDUSTRY KEYWORDS:   Health  Hospitals  Medical Devices  Radiology  Medical Supplies

MEDIA:

Logo
 Logo